As a common affective mental disorder, depressive disorder has currently become the second health burden worldwide, however, its pathogenesis remains to be further elucidated. The clinical treatment of depressive disorder primarily relies on western medicine. However, there is great clinical need for effective and rapid-onset antidepressants for the unsatisfactory effect, obvious treatment time-lag, and intolerable adverse reactions of current drug treatment. Ferroptosis is a novel form of cell death discovered in recent years, which has been found to be involved in the pathogenesis of numerous neurological disorders, including depressive disorder. Currently, some studies have shifted the focus of antidepressant treatment towards targeted inhibition of ferroptosis, and achieved positive outcomes. The present paper provides a comprehensive review of the involvement of ferroptosis in depressive disorder pathogenesis and its potential therapeutic implications, drawing on clinical and preclinical evidence that elucidates the underlying mechanisms linking depressive disorder with ferroptotic processes.

抑郁症是常见的情感类精神障碍疾病，是目前世界范围内第二大健康负担，但其发病机制仍有待明晰。临床抗抑郁症治疗以西药为主，但目前所用药物差强人意的效果、显著的治疗时滞和难以耐受的不良反应，反映出临床对有效和快速起效抗抑郁症药物的巨大需求。铁死亡是近年来发现的新型细胞死亡方式，其参与了包括抑郁症在内的多种神经系统疾病发病进程。目前已有部分研究将目光转向靶向抑制铁死亡的抗抑郁症治疗，并显现出了积极的疗效。本文以抑郁症与铁死亡机制为基础，结合临床与临床前研究，总结了铁死亡参与抑郁症发病机制及其治疗抑郁症的可能性。